RE:Lots of good gouge in this article. Older review and doesn't really say anything that isn't already publicly available via the LABS investor deck, MD&As or even in the Danny Deadlock analysis paper.
I do like that they distinguished that the NDA is actually an investigational NDA mind you since it appears there is still confusion as to what the 'NDA' submissions actually mean. The ANDA is Epiodiolex and will not go anywhere until the litigation is settled between Jazz and whoever the horse is that LABS backed. That may not go anywhere ever.
Current shareholders will not get rich waiting for the traditional pharma play to hit. LABS isn't anywhere near close enough with any of their efforts to hit the big time any time soon.
That said, the wellness and pseudo-pharma play is where the current money is at and it's clear that others see it that way as well. There are reasons why Tilray, Weed and others are making investments into those subsectors. I don't believe LABS needs the pharma moon-shot to hit a 10 banger from here, I think they just need to execute in the jurisdictions they're in and not get left behind, which they are at risk of after the current Q report.
Next Q had better show sizable top line growth or this pig may as well go to the butcher at that point. The market won't wait for LABS to catch up and 'break-even' won't mean squat if growth isn't going along with it.